US Pharma MarketingD&D sees fibrosis improvements, MASH resolution after rolling dice on GLP-1 drug
D&D sees fibrosis improvements, MASH resolution after rolling dice on GLP-1 drug is a pharma and life sciences industry update from FierceBiotech. The story may affect commercial strategy, market access planning, stakeholder engagement, competitive positioning, and near-term monitoring for pharmaceutical and biotech teams.
D&D Pharmatech has linked its GLP-1/glucagon receptor agonist to improvements in liver health, keeping the Korean biotech in the hunt for a market already served by Novo Nordisk’s Wegovy.
Source: FierceBiotech